CXCL16 is activated by p-JNK and is involved in H

Weitao Zhang, Ting Hua, Jiawei Li, Long Zheng, Yifan Wang, Ming Xu, Guisheng Qi

Open access · greenAbstract read

In one paragraph

Article in American journal of translational research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

0.2field-weighted citation impact, top 46% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

CXCL16/ERK1/2 pathway regulates human podocytes growth, migration, apoptosis and epithelial mesenchymal transition.Molecular medicine reports · 2022
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Weitao ZhangDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai Key Laboratory of Organ Transplantation Shanghai 200032, China.

Ting HuaDepartment of Nursing, Zhongshan Hospital, Fudan University Shanghai 200032, China.

Jiawei LiDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai Key Laboratory of Organ Transplantation Shanghai 200032, China.

Long ZhengDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai Key Laboratory of Organ Transplantation Shanghai 200032, China.

Yifan WangDepartment of Pharmacy, The Affiliated East Hospital of Tongji University Shanghai 200123, China.

Ming XuDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai Key Laboratory of Organ Transplantation Shanghai 200032, China.

Guisheng QiDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai Key Laboratory of Organ Transplantation Shanghai 200032, China.

Fudan University · CNShanghai East Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute kidney injury (AKI) leads to an abrupt deterioration of renal function. CXC chemokine ligand 16 (CXCL16) is a CXC-soluble chemokine and a cell surface scavenger receptor that is involved in tissue injury and inflammation. It is induced in AKI patients, but the molecular mechanism remains unclear. In this study, we have worked to determine the function of CXCL16 and to investigate the involvement of ERK and JNK signaling in AKI. We used H

Indexed as

Acute kidney injuryCXCL16CXCR6ERKJNK

Identifiers

PMID30662622

PMCPMC6291717

OpenAlexW2989722201

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.